Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer

Eric Winer, MD

Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and carboplatin.

Eric P. Winer, MD, chief of the Division of Women's Cancers, director of the Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discusses the survival rates of women with early stage breast cancer who received bevacizumab and carboplatin. Winer says that while studies are currnetly being done regarding bevacizumab's effecacy in breast cancer, those studies may not move forward due to this information.